Showcasing Clinical Progress in Complement-Mediated Kidney Diseases & Generating Evidence to Advance Patient Care

• Presenting key efficacy, safety and biomarker findings from a clinical complement therapy program in kidney disease
• Evaluating treatment response across patient populations and assessing how disease biology influences clinical outcomes
• Sharing learnings from trial execution, endpoint selection and patient monitoring to inform future kidney disease development programs

NEW SPEAKING COMPANY

Speakers:

Erich Rajkovic

Chief Business Officer

Stealth Stage Company